{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:05:10Z","timestamp":1785942310061,"version":"3.56.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.eplepsyres.2010.08.006","type":"journal-article","created":{"date-parts":[[2010,9,18]],"date-time":"2010-09-18T04:57:21Z","timestamp":1284785841000},"page":"48-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Is reduced ornithine-\u03b4-aminotransferase activity the cause of vigabatrin-associated visual field defects?"],"prefix":"10.1016","volume":"92","author":[{"given":"Iiris","family":"Sorri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell G.","family":"Brigell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miklos","family":"M\u00e1lyusz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eija","family":"Mahlam\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Capucine","family":"de Meynard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reetta","family":"K\u00e4lvi\u00e4inen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2010.08.006_bib0005","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/019262338701500203","article-title":"A study of the effects of vigabatrin on the central nervous system and retina of Sprague\u2013Dawly and Lister\u2013Hooded rats","volume":"15","author":"Butler","year":"1987","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.eplepsyres.2010.08.006_bib0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00971857","article-title":"Interrelationships between ornithine, glutamate, and GABA II. Consequences of inhibition of GABA-T and ornithine aminotransferase in brain","volume":"13","author":"Daune","year":"1988","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.eplepsyres.2010.08.006_bib0015","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1528-1157.1995.tb01618.x","article-title":"Reduction of plasma alanine aminotransferase during vigabatrin treatment","volume":"36","author":"Foletti","year":"1995","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2010.08.006_bib0020","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1034\/j.1600-0420.2003.00125.x","article-title":"Characterization of vigabatrin-associated optic atrophy","volume":"81","author":"Fris\u00e9n","year":"2003","journal-title":"Acta Ophthalmol. Scand."},{"key":"10.1016\/j.eplepsyres.2010.08.006_bib0025","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1136\/bjo.69.4.283","article-title":"Clinical trials of vitamin B6 and proline supplementation for gyrate atrophy of the choroid and retina","volume":"69","author":"Hayasaka","year":"1985","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.eplepsyres.2010.08.006_bib0030","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1203\/00006450-199809000-00019","article-title":"Gyrate atrophy of the choroid and retina: lymphocyte ornithine-\u03b4-aminotransferase activity in different mutations and carriers","volume":"44","author":"Hein\u00e4nen","year":"1998","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.eplepsyres.2010.08.006_bib0035","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1053\/seiz.2001.0524","article-title":"GABA and the ornithine \u03b4-aminotransferase gene in vigabatrin-associated visual field defects","volume":"10","author":"Hisama","year":"2001","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2010.08.006_bib0040","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/j.0013-9580.2004.01004.x","article-title":"Acute vigabatrin retinotoxicity in albino rats depends on light but not GABA","volume":"45","author":"Izumi","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2010.08.006_bib0045","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ana.21526","article-title":"Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity","volume":"65","author":"Jammoul","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.eplepsyres.2010.08.006_bib0050","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.mcn.2010.01.008","article-title":"Taurine deficiency damages photoreceptors and retinal ganglion cells in vigabatrin-treated neonatal rats","volume":"43","author":"Jammoul","year":"2010","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.eplepsyres.2010.08.006_bib0055","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/archopht.122.7.982","article-title":"Use of an arginine-restricted diet to slow progression of visual loss in patients with gyrate atrophy","volume":"122","author":"Kaiser-Kupfer","year":"2004","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.eplepsyres.2010.08.006_bib0060","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1212\/WNL.53.5.922","article-title":"A gabaergic antiepileptic drug, causes concentric visual field defects","volume":"53","author":"K\u00e4lvi\u00e4inen","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2010.08.006_bib0065","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1167\/iovs.06-0398","article-title":"Ornithine transport via cationic amino acid transporter-1 is involved in ornithine cytotoxicity in retina pigment epithelial cells","volume":"48","author":"Kaneko","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.eplepsyres.2010.08.006_bib0070","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1212\/WNL.50.3.614","article-title":"Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings","volume":"50","author":"Krauss","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2010.08.006_bib0075","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0169-409X(02)00066-2","article-title":"Genetic contribution to variable human CYP3A-mediated metabolism","volume":"54","author":"Lamba","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"6","key":"10.1016\/j.eplepsyres.2010.08.006_bib0080","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2165\/00044011-200020060-00001","article-title":"Visual function in patients treated with the GABAergic anticonvulsant drug tiagabine","volume":"20","author":"Nousiainen","year":"2000","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.eplepsyres.2010.08.006_bib0085","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1620\/tjem.205.335","article-title":"Vitamin B6-responsive ornithine aminotransferase deficiency with a novel mutation G237D","volume":"205","author":"Ohkubo","year":"2005","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.eplepsyres.2010.08.006_bib0090","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0161-6420(00)00587-X","article-title":"Ophthalmologic heterogeneity in subjects with gyrate atrophy of choroid and retina harboring the L402P mutation of ornithine aminotransferase","volume":"108","author":"Peltola","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.eplepsyres.2010.08.006_bib0095","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1212\/WNL.51.6.1779-a","article-title":"Vigabatrin-associated retinal cone dysfunction","volume":"51","author":"Roubertie","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2010.08.006_bib0100","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0014-2999(77)90270-9","article-title":"Audiogenic seizure protection by elevated brain GABA concentration in mice: effects of gamma-acetylenic GABA and gamma-vinyl GABA, two irreversible GABA-T inhibitors","volume":"45","author":"Schechter","year":"1977","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2010.08.006_bib0105","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1212\/WNL.57.2.196","article-title":"Visual field constriction accumulation of vigabatrin but not tiagabine in the retina","volume":"57","author":"Sills","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2010.08.006_bib0110","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1528-1157.1995.tb02576.x","article-title":"A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor","volume":"36","author":"Suzdak","year":"1995","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2010.08.006_bib0115","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1136\/bjo.58.11.907","article-title":"Genetic aspects in gyrate atrophy of the choroid and retina with hyperornithinemia","volume":"58","author":"Takki","year":"1974","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.eplepsyres.2010.08.006_bib0120","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1471-4159.2009.06367.x","article-title":"Cationic amino acid transporter 1-ediated l-arginine transport at the inner blood\u2013retina barrier","volume":"111","author":"Tomi","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.eplepsyres.2010.08.006_bib0125","first-page":"820","article-title":"Prevention of ornithine cytotoxicity by proline in human retinal pigment epithelial cells","volume":"39","author":"Ueda","year":"1998","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.eplepsyres.2010.08.006_bib0130","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1073\/pnas.97.3.1224","article-title":"Correction of ornithine accumulation prevents retinal degeneration in a mouse model of gyrate atrophy of the choroid and retina","volume":"97","author":"Wang","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.eplepsyres.2010.08.006_bib0135","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1111\/j.1528-1157.1999.tb01599.x","article-title":"Characteristics of a unique visual field defect attributed to vigabatrin","volume":"40","author":"Wild","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2010.08.006_bib0140","first-page":"381686","article-title":"A new synaptosomal biosynthetic pathway of glutamate and GABA from ornithine and its negative feedback inhibition by GABA","author":"Yoneda","year":"1982","journal-title":"J. Neurochem."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121110002329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121110002329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:24:35Z","timestamp":1760275475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121110002329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0920121110002329"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2010.08.006","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is reduced ornithine-\u03b4-aminotransferase activity the cause of vigabatrin-associated visual field defects?","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2010.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}